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Abstract
Background
Causes of “true” late kidney allograft failure remain unclear as study selection bias and lim-
ited follow-up risk incomplete representation of the spectrum.
Methods
We evaluated all unselected graft failures from 2008–2014 (n = 171; 0–36 years post-trans-
plantation) by contemporary classification of indication biopsies “proximate” to failure, DSA
assessment, clinical and biochemical data.
Results
The spectrumof graft failure changedmarkedly depending on the timing of allograft failure.
Failures within the first year were most commonly attributed to technical failure, acute rejec-
tion (with T-cell mediated rejection [TCMR] dominating antibody-mediated rejection
[ABMR]). Failures beyond a year were increasingly dominated by ABMR and ‘interstitial
fibrosis with tubular atrophy’ without rejection, infection or recurrent disease (“IFTA”). Cases
of IFTA associated with inflammation in non-scarred areas (comparedwith no inflammation
or inflammation solely within scarred regions) were more commonly associated with epi-
sodes of prior rejection, late rejection and nonadherence, pointing to an alloimmune aetiol-
ogy. Nonadherence and late rejection were common in ABMR and TCMR, particularly
Acute Active ABMR. Acute Active ABMR and nonadherence were associated with younger
age, faster functional decline, and less hyalinosis on biopsy. Chronic and Chronic Active
ABMRwere more commonly associated with Class II DSA. C1q-bindingDSA, detected in
33% of ABMR episodes, were associated with shorter time to graft failure. Most non-biop-
sied patients were DSA-negative (16/21; 76.1%). Finally, twelve losses to recurrent disease
were seen (16%).
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Conclusion
This data from an unselected population identifies IFTA alongside ABMR as a very impor-
tant cause of true late graft failure, with nonadherence-associated TCMR as a phenomenon
in some patients. It highlights clinical and immunological characteristics of ABMR sub-
groups, and should inform clinical practice and individualised patient care.
Introduction
“Late” allograft failure represents a major hurdle in kidney transplantation [1,2]. Refinements
in detection and identification of donor specific antibodies (DSA), and in histological interpre-
tation, highlight the importance of antibodymediated rejection (ABMR) in this process [3–5].
Detailed and informative studies suggest ABMR as the major cause of late graft failure, with a
limited role for T cell mediated rejection (TCMR) or progressive scarring in the absence of an
inflammatory process (interstitial fibrosis/tubular atrophy;IFTA) [3–6].
But the question arises as to whether this is truly representative. Specifically, landmark stud-
ies from the Edmonton [3] and DeKAF study [5] groups showed the deleterious effect of anti-
body-associated inflammation within biopsies from “troubled transplants”. Yet these patients
often experienceddramatic deterioration in function after years of stability, with role of non-
adherence subsequently highlighted in expanded cohorts [4]. Whilst certainly representing one
pathway to graft failure, broader relevance for patients without such trajectories of (dys)func-
tion, who may not necessarily be non-adherent, who may not undergo biopsy, and so may be
under-represented in such studies, is more questionable.
The Mayo Clinic group [6] also identified the importance of ABMR, although this was
based on histology review as DSA data was unavailable. A key strength of this study repre-
sented investigation of an incident cohort, yet this necessarily placed limits on follow-up dura-
tion, with approximately half of studied failures occurringwithin 4 years post-transplantation,
and all within 10 years. The spectrumof causes of “true” late graft failure beyond this time
remains incompletely defined.
In contrast, the Leuven group [7] suggested that for failures specifically beyond 5 years
post-transplantation, IFTA in the absence of prior or current specific diagnosis was more com-
mon, with 12/39 (31%) indication biopsies showing this lesion. The authors acknowledged that
most (76.1%) grafts failing beyond 5 years did not undergo biopsy within 2 years of failure, and
electronmicroscopy and DSA evaluation were unavailable. Nevertheless, other studies of non-
selected graft failures beyond 3 months post-transplantation showed DSA at the time of graft
failure in only 9/69 (13%) patients [8].
In light of this conflicting information we adopted an alternative approach, not dissimilar to
that of a previous study reporting non-immunological risk factors as drivers to late graft fail-
ures [9]. We used a “period analysis” to identify in detail the causes of all unselected graft fail-
ures, including comprehensive histological (including electronmicroscopy) and DSA
evaluation (including C1q-binding DSA).We demonstrate the spectrumof causes of allograft
failure from the post-operative period to many decades post-transplantation. The study con-
firms the importance of ABMR and refines clinico-pathological correlations in light of contem-
porary histological classification [10]. But we also demonstrate the importance of progressive
scarring (IFTA) in the absence of other specific inflammatory diseases in unselected true late
graft failures.
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Materials andMethods
Approach and Rationale
We evaluated the clinical, histological and immunological data in all non-selected transplant
failures occurringbetween 2008 and 2014 in patients at a single transplant centre. This repre-
sents an era during which liberal HLA antibody testing was undertaken using solid-phase
screening and identification. In addition, we incorporated indication transplant biopsies more
liberally in the program, often performedmany years from transplantation when graft dysfunc-
tion may previously have been dismissed as inevitable and non-modifiable. Biopsies were
undertaken at the discretion of the treating clinical team, in general based on unexplained
renal dysfunction (~10% rise in creatinine), and/or worsening proteinuria.
The study was conducted according to the Declaration of Helsinki and Istanbul and follow-
ing permission and approval from the local research and audit office of University Hospital
Birmingham. In regard to the center’s clinical practice, none of the transplant donors were
from a vulnerable population and all donors or next of kin provided written informed consent
that was freely given.
Histological, Immunological and Clinical Data
Pathologists with specific expertise in renal pathology reported all biopsies. Each biopsy quali-
fier was graded according to the Banff classification and electronically stored. For this study,
these records were reviewed in the context of the recently updated Banff ABMR classification
[10], the available DSA data, and the clinical scenario. Histological features of ABMR (micro-
vascular inflammation; peritubular/glomerularbasement membrane changes on electron
microscopy; C4d deposition) were specifically recorded; polyclonal anti-C4d antibody staining
(Biomedica) was used on formalin-fixed paraffin-embeddedsections with low pH antigen
retrieval; conventional staining (immunoperoxidase) was used to evaluate (recurrent or de
novo) glomerulonephritis; glutaraldehyde fixation was used for electronmicroscopy sample
processing.
Samples for circulatingDSA were always tested at the time of biopsy and graft failure
(return to dialysis or retransplantation), and at other times according to clinician approach.
For patients returning to dialysis, testing was undertaken prior to immunosuppression wean-
ing; for patients undergoing pre-emptive retransplantation, testing was undertaken prior to
retransplantation. Solid-phase assays (Luminex) screened for and then subsequently identified
specificities of circulatingHLA antibodies (One Lambda). For patients demonstrating HLA
antibodies, the presence of C1q-binding antibodies was evaluated using single flow bead assays
according to manufacturers’ instructions (C1qScreen;One Lambda). Samples stored prior to
transplantation were retrospectively tested to evaluate whether DSA was pre-existing or de
novo post-transplantation.
Information regarding episodes of rejection, non-adherence, and measurements of esti-
mated glomerular filtration rate (MDRD eGFR) and proteinuria (early morning “spot” urine
albumin:creatinine ratio [ACR]) were obtained from clinical records and laboratory databases.
Transplant Failure: timing and aetiology
Transplant failures were identified from the prospectively maintained departmental database,
cross checked with data supplied by the National Registry (National Health ServiceBlood and
Transplant; NHSBT). Only death-censored graft failures were evaluated. One hundred and sev-
enty-one graft failure were identified. Twenty additional patients were identified by NHSBT
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whose grafts failure during this period but had left the region. Their demographics were similar
to the 171 who underwent follow-up locally (data not shown) and were not studied further.
For perspective, during this period, the department followed a prevalent population of
between 1200 and 1400 patients; between 2008 and 2014 the department undertook 978 trans-
plant procedures; during this period a further 149 patients died with ongoing graft function.
The 171 studies failures were then grouped depending on time to failure: within 1 month; 1
month to 1 year; 1–5 years; 5–10 years;>10 years.
The causes of graft failures were classified following a similar (but not identical) strategy to
that of El-Zoghby [6]:
‘primary non-function’: usually resulting from renal transplant arterial or venous thrombo-
sis. In a minority of cases (see “results”) kidney function insufficient to avoid dialysis, but in
the absence of a defined “surgical”/”technical” cause was evident, probably representing severe
preservation injury.
‘ABMR’: as defined in the recently updated Banff classification [10], and comprising the
triad of circulating DSA, tissue injury, and evidence of antibody/endothelium interaction
(based either on the magnitude of microcirculatory inflammation or C4d deposition; gene
expression studies were not undertaken).
‘TCMR’: tubulo-interstitial immune infiltrates, with or without involvement of large vessels;
microvascular inflammation (glomerulitis; peritubular capillaritis) in the absence of a detect-
able anti-HLA antibody was included in this category on the basis that these lesions are recog-
nised previously as a nonspecific component of rejection [11,12]. It should be acknowledged
though that these lesions may also represent ABMR as a result of non-HLA antibodies which
were not evaluated in the current study. Therefore whilst it can be cogently argued that these
lesions represent “possible ABMR”, aetiological certainty is impossible and so we have kept the
label “TCMR” whilst highlighting the possibility of ABMR in some patients (a small minority)
in the relevant section of “results”.
‘recurrent disease’: histological evidence of the same disease process that led to failure of the
patient’s native kidneys
‘de novo’ glomerulonephritiswas diagnosed in the context of a known primary nephropathy
different to the disease seen in the transplant kidney
‘PVIN’: ‘polyoma virus interstitial nephropathy’; evidenced by characteristic viral inclusions
on biopsy, positive staining for SV40 antigen, accompanied by circulatingDNAemia. Graft fail-
ures from acute rejection following immunosuppression minimisation as treatment for PVIN
were classified as PVIN, rather than rejection.
‘surgical’: resulting from vascular or ureteric complications beyond the immediate post-
operative period.
‘medical’: transplant failure following an episode of acute kidney injury in the context of
intercurrent severe illness without other defined renal aetiology.
‘IFTA’: interstitial fibrosis and tubular atrophy as the only abnormal histological finding, in
the absence of other inflammatory or infective lesions described above.
Timing of Transplant Biopsies
We primarily considered the biopsy taken most proximate to graft failure as most informative,
or the first in a series of biopsies taken in quick succession (usually in the context of acute rejec-
tion). All biopsies were indication biopsies, and therefore should capture the prevailing
(immune-) pathological scenario. Importantly, we set the following time limits in regard to
using biopsies as “diagnostic”:
Within 2 months of graft failure for failures within 1 year
Renal Allograft Failure Spectrum
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Within 6 months of graft failure for failures within 5 years
Within 12 months of graft failure for failures within 10 years
Within 24 months of graft failure for failures beyond 10 years
Although biopsies taken outside these timeframes were not considered diagnostic of graft
failure, their findings are describedwhere relevant and contributory. We acknowledge that not
all patients underwent biopsy; nevertheless their clinical characteristics and DSA results may
offer some insights and they are accordingly described in “results”.
Statistical analysis
Data are presented as mean ± standard deviation unless stated otherwise.Continuously distrib-
uted data were compared using ANOVA and Students’ t-test, and categorical data by means of
chi-squared testing. A type 1 error rate less than 5% (p0.05) was considered statistically
significant.
Results
The spectrumof Graft Failure
Demographics of the 171 studied patients are shown in Table 1, and their causes of graft failure
in Fig 1.
Early failures (within 1 month post-transplantation) were exclusively due to primary non
function (n = 33), either vascular thrombosis (n = 28) or lack of functionwithout identifiable
cause and presumed either due to suboptimal “donor quality” or “preservation injury” (n = 5
with early biopsies showing acute tubular injury without inflammation or detectable DSA).
Subsequent graft failures were far more heterogeneous and included ABMR (n = 27), IFTA
(n = 29), recurrent disease (n = 22), TCMR (n = 14), and PVIN (n = 5). Of the 22 cases of
recurrent disease, 2 cases (both IgA nephropathy) were in the context of an unknown primary
diagnosis. These probably represented recurrent disease, although de novo glomerulopathy
could not be excluded.
‘Proximate’ biopsy data (timing defined in “methods”) was available in all 97 cases. The
mean time between biopsy and graft failure was 4±2 weeks for failures within 1 year, 4±3
months for failures within 5 years, 7±4 months for failures within 10 years, and 14±5 months
for failures beyond 10 years.
Medical complications (n = 11, usually severe sepsis), surgical complications beyond the
immediate post-operative period (n = 6), and transplant nephrectomy for either PTLD or car-
cinoma (n = 3) were also contributors to graft failure; these grafts did not undergo biopsy.
Twenty-one grafts failed without undergoing “proximate” biopsy, representing 12.3% of all
graft failures (21/171), and 17.7% of graft failures beyond a month, after excluding medical and
surgical causes, and nephrectomies [21/(97+21)].
AntibodyMediated Rejection (ABMR). Twenty-seven grafts failed to ABMR. DSA was
present at the time of biopsy, and persisted to the time of graft failure; all DSA developed de
novo post transplantation (exact timing unknown). Subclassification of graft failures was as fol-
lows: Acute Active ABMR (n = 9); Chronic Active ABMR (n = 15); Chronic ABMR (n = 3). All
except 4 patients displayed microvascular damage (glomerulitis, peritubular capillaritis [PTCi-
tis], transplant glomerulopathy or peritubular capillary basement membrane multilamellation
[PTCBMML]) as histological qualifiers; 3 patients with Chronic Active ABMR and 1 patient
with chronic ABMR displayedmacrovascular changes (vasculitis and chronic intimal thicken-
ing respectively) without microvascular damage or inflammation.
Biopsies showing Acute Active ABMR displayed more glomerulitis and PTCitis than biop-
sies displaying Chronic Active ABMR (Table 2). All biopsies with Chronic Active ABMR
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displayed C4d staining; C4d staining was absent in 3/9 (33%) patients with Acute Active
ABMR–these patients met criteria for Acute Active ABMR based on microcirculation inflam-
mation in the absence of C4d staining. Biopsies displaying Chronic ABMR displayed numeri-
cally (but not statistically) more chronic glomerulopathy and PTCBMML.
The characteristics of patients and DSA are also shown in Table 2. Time to graft failure was
shorter, and age at graft failure younger, in patients with Acute Active ABMR compared with
the other 2 histological groups. Faster decline in graft function (using eGFR 6 months prior to
failure as a proxy) was also evident in the Acute Active ABMR group (excluding a single patient
whose graft failed before 6 months post-transplantation). Non-adherence was noted in 66% of
patients with Acute Active ABMR, compared with 33% with Chronic Active ABMR, and none
with Chronic ABMR (p = 0.002).
Table 1. Demographics of 171 studiespatients experiencing graft failure.
Characteristic
Age of Transplant (years) 38 ± 15
Sex Male: 105; Female: 66
Ethnicity White: 132; South Asian: 29; Black: 9; Chinese: 1
HLAMismatch 2.6 ± 1.4 Ag
PRA at transplant (%) Median: 0 (IQR 1–5)
Repeat Transplant 43
Donor Age (years) 45 ± 14
Live Donor 41
Donor following Cardiac Death 2
Cause of Renal Faliure
Glomerular 49
Cystic 34
Diabetes 25
Hypertension 32
Other 21
Date of Transplant
1990 and before 21
1991–1995 17
1996–2000 31
2001–2005 33
2006–2010 49
Since 2011 20
Immunosuppression at transplantation
Prednisolone 160
Azathioprine 92
Mycophenolate 79
Ciclosporin 90
Anti CD25MAb 94
Time to Graft Failure
Average (days) 3103 ± 2927
Median (days) 2343 (IQR 127–5032)
Range (days) 0–13743 (37.6 years)
doi:10.1371/journal.pone.0162278.t001
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Finally, ah-scores were lower in patients with Acute Active ABMR (Table 2); six displayed
ah-scores of zero. Notable differences in ah-score were also seen between adherent and non-
adherent patients with ABMR: 2.00±1.02 versus 0.25±0.66 (p<0.001).
DSA Class and C1q-binding DSA in ABMR. Class II DSA was more common in patients
with Chronic Active or Chronic ABMR, compared with Acute Active ABMR (Table 2). No dif-
ference between groups for Class I DSA was evident.
Nine patients (33% of patients with ABMR) displayed C1q-binding DSA (class I n = 1;
Class II n = 4;Both n = 4), with no difference across histological subgroups. Mean time to graft
failure was shorter in patients with C1q-binding DSA (2454 versus 4759 days; p = 0.05).
Interstitial Fibrosis and Tubular Atrophy (IFTA). Twenty-nine grafts failed with only
IFTA on indication biopsy proximate to failure. None showed microcirculatory inflammation,
vasculitis or C4d deposition; DSA was absent in all at the time of biopsy and at graft failure.
Banff ci and ct scores were universally2.
By definition, no cases displayed interstitial infiltrates meeting acute rejection criteria
(including borderline change). However, milder interstitial inflammation was seen in some
biopsies, as was inflammation in scarred areas. We therefore segregated IFTA cases into 3
groups (Table 3): IFTA without inflammation (n = 15); IFTA with inflammation confined to
areas of scarring (n = 6); IFTA with inflammation outside scarred areas (n = 8).
As defined, these groups displayed notable clinical differences. Specifically, patients display-
ing IFTA with inflammation in non-scarred areas had more likely experiencedprior rejection
Fig 1. Causes of graft failure by period following transplantation.
doi:10.1371/journal.pone.0162278.g001
Renal Allograft Failure Spectrum
PLOSONE | DOI:10.1371/journal.pone.0162278 September 20, 2016 7 / 15
(any grade;any time), late rejection (>12 months post-transplantation), and nonadherence
(p0.01 for all). No patients in other IFTA groups displayed nonadherence or late rejection.
Table 2. Characteristics of patientsdisplaying ABMRon indicationbiopsy.
Characteristic ABMR—Acute Active (n = 9) ABMR—Chronic Active (n = 15) ABMR—Chronic
(n = 3)
p value
Time to Graft Failure (days) 1936 ± 1857 5025 ± 2927 6446 ± 2536 0.01
Age at transplant (years) 26 ± 5 27 ± 12 24 ± 5 NS
Age at graft transplant (years) 31 ± 7 41 ± 11 41 ± 6 0.03
eGFR 6 months prior to graft failure (ml/min) 42.6 ± 19.9 21.0 ± 7.4 16.0 ± 1.4 <0.001
UACR at graft failure (mg/mmol) 37 ± 48 289 ± 193 72 ± 31 0.001
Previous rejection 0 5 (33%) 0 0.04
Non-adherence 6 (66%) 5 (33%) 0 0.002
Class I DSA 4 (44%) 6 (40%) 1 (33%) NS
Class II DSA 1 (11%) 7 (47%) 2 (66%) 0.04
Class I + II DSA 4 (44%) 2 (13%) 0 0.05
C1q-binding DSA 4 (44%) 4 (27%) 1 (33%) NS
g-score 1.49 ± 0.82 0.47 ± 0.96 0 0.05
ptc-score 1.56 ± 0.68 0.67 ± 0.94 0 0.03
C4d 6 (66%) 15 (100%) 0 NS*
cg-score 0 1.33 ± 0.88 2.33 ± 0.47 NS**
PTCBMML 0 8 (53%) 3 (100%) NS**
ah- score 0.44 ± 0.68 2.30 ± 1.12 1.90 ± 0.94 0.001
ci-score 1.66 ± 0.94 2.53 ± 0.61 2.30 ± 0.47 0.01
*Comparison made excluding “Chronic ABMR” which by definition lacks C4d deposition (or would have otherwise been classified as “Chronic Active
ABMR”);
**Comparisonmade excluding “Acute Active ABMR” which by definition lacks chronic histological qualifiers (cg or PTCBMML) or would have otherwise
been classified as “Chronic Active A.
doi:10.1371/journal.pone.0162278.t002
Table 3. Characteristics of patientsdisplaying IFTA on indicationbiopsy.
Characteristic IFTA without inflammation
(n = 15)
IFTA with inflammation in scarred
areas (n = 6)
IFTA with inflammation in non-
scarred areas (n = 8)
p value
Time to Graft Failure (days) 6101 ± 2147 4525 ± 2147 3325 ± 1867 0.002
Age at transplant (years) 31 ± 10 47 ± 11 28 ± 7 0.001
Age at graft transplant (years) 48 ± 10 61 ± 11 38 ± 9 <0.001
eGFR 6 months prior to graft
failure (ml/min)
13.5 ± 1.5 15.8 ± 2.9 20.5 ± 5.5 <0.001
UACR at graft failure (mg/mmol) 168 ± 103 235 ± 189 116 ± 93 0.06
Rejection (any grade; any time) 2 (13%) 0 5 (62%) 0.003
Late (>12months) rejection 0 0 3 (38%) 0.003
Non-adherence 0 0 2 (25%) 0.01
% GS 42 ± 21 61 ± 12 28 ± 18 0.02
cv-score 1.9 ± 0.7 2.0 ± 1.0 1.13 ± 0.93 0.02
ah-score 2.1 ± 0.83 1.83 ± 0.9 1.38 ± 0.99 NS
i-score 0 0 1.0 ± 0.5 NA*
t-score 0 0 0.8 ± 0.5 NA*
*N/A = Not analysed; i- and t-scores presented in regard to inflammation in non-scarred areas, which was only the case for one of the groups specifically
defined a priori. Therefore statistical analysis inappropriate
doi:10.1371/journal.pone.0162278.t003
Renal Allograft Failure Spectrum
PLOSONE | DOI:10.1371/journal.pone.0162278 September 20, 2016 8 / 15
Time to graft failure was shorter, and renal function declinemore rapid, in patients with
inflammation in non-scarred areas compared with the other groups (p<0.05 for all compari-
sons). Proteinuria at biopsy was numerically lower when inflammation in non-scarred areas
was seen (p = 0.06). Interestingly, many patients with IFTA displayed marked proteinuria, but
this was a manifestation of increasing glomerulosclerosis as part of the scarring process; pro-
teinuria was highly correlated with the percentage of globally sclerosed glomeruli on biopsy in
these patients with IFTA (r = 0.63; p = 0.01; Fig 2). By definition, this glomerulosclerosiswas
not a manifestation of recurrent (or de novo) glomerular diseases, which were considered as a
separate category of graft failures.
Percentage glomerulosclerosis, “cv” and “ah” scores were all lower in biopsies displaying
IFTA with inflammation in non-scarred areas compared with the other 2 groups (p = 0.02 for
both comparisons). The paucity of patients not treated with CNI precluded evaluation of the
role of CNI exposure in the development of IFTA. More patients with graft failure classified as
IFTA were treated with ciclosporin than tacrolimus, but this is confounded by the more recent
introduction of tacrolimus into clinical practice coupled with the increased time post trans-
plantation at which IFTA graft failures occurred.
T-Cell Mediated Rejection (TCMR). TCMR was seen on indication biopsy in 14 patients.
All cases met criteria for Banff 1B rejection.Histological features are shown in Fig 3. Nonad-
herence was an important factor in TCMR (n = 7). Two features suspicious for ABMRwere
seen on 6 biopsies, specifically the presence of microcirculatory inflammation (n = 4) or
Fig 2. Relationship betweenproteinuria (earlymorning “spot” albumin:creatinine ration;UACR) and percentage
glomerulosclerosis in patients with IFTA on indicationbiopsyproximate to graft failure (n = 25).
doi:10.1371/journal.pone.0162278.g002
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circulating (de novo) DSA (n = 2). However, these characteristics were mutually exclusive (Fig
3) and so no biopsy met current criteria for ABMR (note non-HLA antibodies were not tested
as potential causes of microcirculation inflammation). The other 8 patients displayed TCMR
without either DSA or microcirculation injury.
Characteristicsof patients not undergoing biopsies. Twenty-one grafts failed without an
obvious identifiable cause or proximate biopsy. These grafts failed late after transplantation (all
beyond 5 years and most beyond 10 years; Fig 1), and represented 21.9% of failures beyond 5
years (21/96). DSA (all de novo) was detectable in 5 patients, with 16 demonstrating no DSA.
These 2 groups did not differ numerically or statistically for any evaluated demographic or
Fig 3. Characteristics of patientsdisplaying TCMRon indicationbiopsy.Microcirculation injury evident in 4 patients. None displayed
circulating donor-specific HLA antibodies or C4d staining and therefore did not fulfil current criteria for ABMR. In addition to interstitial infiltrates
these patients displayed the following: glomerulitis n = 1; chronic transplant glomerulopathy n = 1; chronic transplant glomerulopathy with
nonadherence n = 1; glomerulitisand chronic transplant glomerulopathy with nonadherence n = 1.
doi:10.1371/journal.pone.0162278.g003
Renal Allograft Failure Spectrum
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clinical factors, with slow progression to failure and moderate proteinuria at the time of failure
(Table 4).
Causes of Late, UnselectedGraft Failures. The causes of graft failure beyond 5, 10 and 15
years (with absolute numbers) are shown in (Fig 4A–4C). Note that graft failures comprising
each summary figure will overlap, but the temporal relationships can be discerned by present-
ing the data in this way. Although a spectrumof aetiologies is seen, the dominant drivers to
late graft failure are ABMR, IFTA and ‘chronic graft attrition’ not undergoing biopsy. Particu-
larly at later times, ABMR is dominated by biopsies demonstrating chronic lesions, and IFTA
cases are dominated by those not displaying concomitant inflammation. Beyond 15 years,
IFTA was the commonest biopsy finding (n = 12), followed by definite/probable ABMR
(biopsy-proven:n = 6; non-biopsied with DSA: n = 2), followed by non-biopsied cases with no
detectable DSA (n = 7). With the exception of patient age (whereby patients with graft failures
categorised as ABMR or TCMR were younger at the time of transplantation and at the time of
graft failure than those classified as IFTA or ‘chronic graft attrition’ [p<0.05 for all compari-
sons]), no other baseline demographics were associated with differing causes of graft failure.
Discussion
Very appropriately ABMR is considered a major cause of late graft failure. This study confirms
its importance, and refines clinic-pathological correlations in the context of contemporary his-
tological classification and antibody evaluation. Yet the attention to ABMR has beenmirrored
by the concept that other causes of graft failure, in particular progressive scarring (“IFTA”), are
unimportant. The current study opposes this prevailing view by examining unselected patients
with true late graft failure, which by virtue of design and duration of previous studies have
been incompletely represented hitherto. Acknowledging this heterogeneity informs practice,
and suggests individualisation of therapy directed towards the prevailing mechanism.
The close relationship betweenDSA and histological ABMR speaks to the robustness of the
current histological classification [10], including more recently described lesions of ABMR
(vasculitis; chronic intimal thickening; C4d-negative ABMR) which were all seen in this cohort.
Differences betweenABMR subgroups were seen, most notably faster progression to graft fail-
ure and a particularly high incidence of nonadherence (66%) in Acute Active ABMR. Interest-
ingly, ah-scores were lower in Acute Active ABMR and in nonadherent patients. Although
Table 4. Characteristics of patientsnot undergoing transplantbiopsy proximate to graft failure.
Characteristic No Biopsy; DSA negative (n = 16) No Biopsy;DSA positive (n = 5) p value
Time to Graft Failure (days) 5518 ± 2147 6582 ± 2147 NS
Age at transplant (years) 36 ± 12 30 ± 16 NS
Age at graft transplant (years) 51 ± 13 49 ± 16 NS
Donor Age 43 ± 13 44 ± 13 NS
Live Donor 2 (13%) 0 NS
eGFR 6 months prior to graft failure (ml/min) 15.0 ± 4.2 12.0 ± 1.8 NS
UACR at graft failure (mg/mmol) 127 ± 64 126 ± 69 NS
Previous rejection 2 (12%) 0 NS
Non-adherence 0 0 NS
Class I DSA 0 1 (20%) NA
Class II DSA 0 2 (40%) NA
Class I + II DSA 0 2 (40%) NA
C1q-binding DSA 0 0 NA
doi:10.1371/journal.pone.0162278.t004
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nonspecific, arteriolar hyalinosis nevertheless represents a component of calcineurin-inhibitor
nephrotoxicity, and therefore (inappropriately) lower CNI exposuremay underlie this observa-
tion, and in part explain previous observations linking arteriolar hyalinosis to improved graft
outcome [3,7].
C1q-binding DSA were found in 33% of patients with ABMR. Although their frequencywas
similar across subgroups of ABMR, they were associated with shorter time to graft failure, per-
haps representing a marker of more aggressive alloimmunity. This certainly resonates with the
brisk rates of failure seen in patients displaying these antibodies previously [13].
Nonadherence was also found in 50% of patients with TCMR-associated graft failure, which
was seen at all times beyond 1 month. The paucity of TCMR-related failure beyond 10 years
(n = 3) is broadly in keeping with, although not perfectly aligned to, recent findings suggesting
complete absence of TCMR on indication biopsies beyond 10 years [14]. Indeed the true con-
tribution of TCMRmay be understated given the lack of protocol biopsies and the possible
contribution of TCMR in some cases labelled as predominant ABMR. Some patients with
TCMR displayed microvascular inflammation, which is a recognisedphenomenon. Although
Fig 4. Breakdown of causes of graft failure beyond 5 years (4a), 10 years (4b) and 15 years (4c) post-transplantation,with each figure
representing the graft failure distribution between the time pointmentioned and the time of graft failure.Note therefore that graft failures
comprising each summary figure will overlap, but the temporal relationships can be discerned by presenting the data in this way.
doi:10.1371/journal.pone.0162278.g004
Renal Allograft Failure Spectrum
PLOSONE | DOI:10.1371/journal.pone.0162278 September 20, 2016 12 / 15
(by definition) no circulating anti-HLADSA was detected, and although it has been said that
detection of anti-HLADSA is a prerequisite for ABMR diagnosis [11], it is conceivable these
cases represent ABMR secondary to non-HLA antibodies, which were not tested routinely. But
in fact, at least in this series, such misclassificationwould only pertain to 2 patients (Fig 3).
Also not undertakenwere gene expression studies to identify “antibody/endothelial interac-
tion”. But again such information would not have improved classification, as cases with DSA
displayed no evidence of the (vascular) “tissue” injury required for diagnosingABMR (Fig 3)
[10]. That is not, however, to dispute that gene expression research does continues to refine
our understanding of transplantation injury, although its clinical and diagnostic utility is still
evolving.
Advanced fibrosis (“IFTA”) in the absence of defined immune/inflammatory lesions was a
major cause of graft failure in this series, particularly for late graft failures. Other studies sug-
gest this lesion to be unimportant, although their design was such that IFTA was likely under-
represented as discussed above [3–6]. Even so, and in support of our current findings, it should
be noted that broadly similar timepoints post-transplantation the prevalence of graft failure
from IFTA in the important study from the Mayo Clinic [6] was actually similar to the current
study. Specifically, failures due to IFTA in the absence of identifiable underlying cause was 5.8%
after mean follow-up 5 years versus 5.5% [4/73] within 5 years in the current study. Beyond 5
and 10 years post-transplantation failures became increasingly biased towards IFTA which
therefore represented a dominant finding in “true” late graft failure. And it is precisely these
failures at these late times which have proven so resistant to the advances and evolution of
transplantation practice during the last 25 years [1,2].
Inflammation was seen in some biopsies with IFTA, in the absence of other inflammatory
diagnoses. This was either restricted to areas of scarring, or present in non-scarred areas but by
definition not meeting criteria for rejection. Subgroup analysis revealed interesting clinico-
pathological correlations. Specifically, nonadherence and late rejection episodes were unique to
the group with inflammation in non-scarred areas, with these patients experiencing brisker
functional decline.We contend that this biopsy findingmay represent a low-grade alloimmune
response, and attention to adherence and immunosuppression is mandatory.
Yet the majority of patients with IFTA displayed either no inflammation or inflammation
restricted to scarred areas. The clinical characteristics of patients with these findings were simi-
lar, without an abundance of rejection or nonadherence, and similar rate of graft decline.We
therefore contend that inflammation within areas of transplant fibrosis may represent a non-
specific feature of the scarring process itself, which indeed is recognised elsewhere [15]. Other
studies have demonstrated inflamed scarring within transplants as a component of other pro-
gressive inflammatory diseases [16], but this was not relevant in the current study which classi-
fied such inflammatory diseases entirely separately. For those patients who did not undergo
biopsy, by comparing these patients (Table 4) alongside patients with ABMR and IFTA (Tables
2 and 3 respectively), one can speculate that the non-biopsied patients with DSA (n = 5) most
closely resembled Chronic Active or Chronic ABMR, and those without DSA (n = 16) resem-
bled those with IFTA either without inflammation or with inflammation in non-scarred areas.
An important question stemming from the current study is why IFTA may progress in the
absence of inflammatory disease, a process previously coined “mysterious dysregulated fibro-
sis” [4,17]. Recent reports offer new insights into this process and include epigenetic mecha-
nisms resulting in constitutive fibroblast activation [18] and re-expression of embryonic genes
from injured tissue resulting in maladaptive downstream fibrogenesis [19]; fibrosis results in
local hypoxia, resulting in hypoxic damage to neighbouring tissue and a self-perpetuating cycle
of damage [20]; reduced nephron mass with associated glomerular hyperfiltration and protein-
uria are mechanisms more specific to the anatomical structure of the kidney [21]. Thus
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“fibrosis begets fibrosis”, and therapies directed towards this phenomenon, which are emerging
in native kidney disease will hopefully prove their worth in transplantation [22]. Finally, the
prevalence of severe arteriolar hyalinosis in grafts with IFTA (in particular in when IFTA was
present without concomitant inflammation) also speaks to a role for chronic CNI toxicity that
should not be forgotten [23–26].We intentionally avoided attempts to link therapeutic changes
with outcome, as conclusions are unlikely to offer insight beyond existing evidence, and may
indeed be misleading.We believe it is unlikely that we missed antecedent inflammation (espe-
cially ABMR) on biopsies ultimately classified as “IFTA” in light of our biopsy practice, and
also the lack of either acute or chronic ABMR (and absent DSA) on such biopsies classified
thus.
The results of the current study require interpreting in the context of the changing face of
transplant immunosuppression and donor/recipient demographics. The design of the study
does not lend itself to interpretation of the influence of changes in clinical practice over time,
and the results require careful interpretation in that context. Yet in parallel, a major strength is
the examination of “true” late graft failure. It affirms the importance of ABMR in late graft loss,
and highlights the importance of progressive fibrosis as important pathway to graft failure and
target for intervention. This understanding of the true spectrumof graft failure is an important
step in improving clinical practice by individualising patient care.
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